Patents by Inventor Kim Lee Sim
Kim Lee Sim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220323562Abstract: Disclosed is the attenuated Salmonella typhi vaccine Ty21a utilized as a vector for Shigella and/or enterotoxogenic E. coli genes stably integrated in the Ty21a chromosome. These genes include a heterologous Shigella sonnei O-antigen biosynthetic gene region that comprises the wzz gene and expresses Shigella sonnei form 1 O-antigen, as well as a heterologous acid resistance biosynthetic gene system comprising a YbaS gene, which enables increased stability of the Ty21a vector at pH 2.5 relative to Ty21a without the integrated acid resistance biosynthetic gene system.Type: ApplicationFiled: April 25, 2022Publication date: October 13, 2022Inventors: Yun WU, Dennis J. KOPECKO, B. Kim Lee SIM, Stephen L. HOFFMAN
-
Publication number: 20220233681Abstract: Disclosed herein are transgenic Salmonella typhi Ty21a comprising a chromosome with one or more heterologous nucleic acid regions, wherein the heterologous nucleic acid regions encode one or more viral antigens and are integrated into the Salmonella typhi Ty21a chromosome, and wherein the transgenic Salmonella typhi Ty21a stably expresses the one or more viral antigens. Also disclosed herein are compositions and vaccines comprising the transgenic Salmonella typhi Ty21a. Also disclosed herein are methods of eliciting an immune response in a subject against a SARS-CoV-2 viral antigen and/or a Salmonella typhi antigen comprising administering one or more doses of the composition or the vaccine to the subject. Also disclosed herein are methods of treating, preventing or reducing the incidence of COVID-19 and/or typhoid fever in a subject comprising administering one or more doses of the composition or the vaccine to the subject.Type: ApplicationFiled: December 31, 2021Publication date: July 28, 2022Inventors: Betty Kim Lee SIM, Tint Tint WAI, Ehud INBAR, Stephen L. HOFFMAN
-
Patent number: 11324814Abstract: Disclosed is the attenuated Salmonella typhi vaccine Ty21a utilized as a vector for Shigella and/or enterotoxogenic E. coli genes stably integrated in the Ty21a chromosome. These genes include a heterologous Shigella sonnei O-antigen biosynthetic gene region that comprises the wzz gene and expresses Shigella sonnei form 1 O-antigen, as well as a heterologous acid resistance biosynthetic gene system comprising a YbaS gene, which enables increased stability of the Ty21a vector at pH 2.5 relative to Ty21a without the integrated acid resistance biosynthetic gene system.Type: GrantFiled: June 10, 2020Date of Patent: May 10, 2022Assignee: Protein Potential, LLCInventors: Yun Wu, Dennis J. Kopecko, B. Kim Lee Sim, Stephen L. Hoffman
-
Publication number: 20200376107Abstract: Disclosed is the attenuated Salmonella typhi vaccine Ty21a utilized as a vector for Shigella and/or enterotoxogenic E. coli genes stably integrated in the Ty21a chromosome. These genes include a heterologous Shigella sonnei O-antigen biosynthetic gene region that comprises the wzz gene and expresses Shigella sonnei form 1 O-antigen, as well as a heterologous acid resistance biosynthetic gene system comprising a YbaS gene, which enables increased stability of the Ty21a vector at pH 2.5 relative to Ty21a without the integrated acid resistance biosynthetic gene system.Type: ApplicationFiled: June 10, 2020Publication date: December 3, 2020Applicant: Protein Potential, LLCInventors: Yun WU, Dennis J. KOPECKO, B. Kim Lee SIM, Stephen L. HOFFMAN
-
Patent number: 10695415Abstract: Disclosed is the attenuated Salmonella typhi vaccine Ty21a utilized as a vector for Shigella and/or enterotoxogenic E. coli genes stably integrated in the Ty21a chromosome. These genes include a heterologous Shigella sonnei O-antigen biosynthetic gene region that comprises the wzz gene and expresses Shigella sonnei form 1 O-antigen, as well as a heterologous acid resistance biosynthetic gene system comprising a YbaS gene, which enables increased stability of the Ty21a vector at pH 2.5 relative to Ty21a without the integrated acid resistance biosynthetic gene system.Type: GrantFiled: July 6, 2016Date of Patent: June 30, 2020Assignee: Protein Potential, LLCInventors: Yun Wu, Dennis J. Kopecko, B. Kim Lee Sim, Stephen L. Hoffman
-
Patent number: 10272146Abstract: Disclosed are substantially purified Plasmodium sporozoites and preparations of Plasmodium sporozoites substantially separated from attendant non-sporozoite material, where the preparations of Plasmodium sporozoites have increasing levels of purity. Vaccines and pharmaceutical compositions comprising purified Plasmodium sporozoites are likewise provided. Methods of purifying preparations of Plasmodium sporozoites are also provided.Type: GrantFiled: March 14, 2017Date of Patent: April 30, 2019Assignee: Sanaria Inc.Inventors: B. Kim Lee Sim, Minglin Li, Richard E. Stafford, Stephen L. Hoffman
-
Publication number: 20180264099Abstract: Disclosed is the attenuated Salmonella typhi vaccine Ty21a utilized as a vector for Shigella and/or enterotoxogenic E. coli genes stably integrated in the Ty21a chromosome. These genes include a heterologous Shigella sonnei O-antigen biosynthetic gene region that comprises the wzz gene and expresses Shigella sonnei form 1 O-antigen, as well as a heterologous acid resistance biosynthetic gene system comprising a YbaS gene, which enables increased stability of the Ty21a vector at pH 2.5 relative to Ty21a without the integrated acid resistance biosynthetic gene system.Type: ApplicationFiled: July 6, 2016Publication date: September 20, 2018Applicant: Protein Potential, LLCInventors: YUN WU, Dennis J. KOPECKO, B. Kim Lee SIM, Stephen L. HOFFMAN
-
Publication number: 20170274061Abstract: Disclosed are substantially purified Plasmodium sporozoites and preparations of Plasmodium sporozoites substantially separated from attendant non-sporozoite material, where the preparations of Plasmodium sporozoites have increasing levels of purity. Vaccines and pharmaceutical compositions comprising purified Plasmodium sporozoites are likewise provided. Methods of purifying preparations of Plasmodium sporozoites are also provided.Type: ApplicationFiled: March 14, 2017Publication date: September 28, 2017Applicant: Sanaria Inc.Inventors: B. Kim Lee SIM, Minglin Li, Richard E. Stafford, Stephen L. Hoffman
-
Patent number: 9616115Abstract: Disclosed are substantially purified Plasmodium sporozoites and preparations of Plasmodium sporozoites substantially separated from attendant non-sporozoite material, where the preparations of Plasmodium sporozoites have increasing levels of purity. Vaccines and pharmaceutical compositions comprising purified Plasmodium sporozoites are likewise provided. Methods of purifying preparations of Plasmodium sporozoites are also provided.Type: GrantFiled: January 21, 2016Date of Patent: April 11, 2017Assignee: SANARIA INC.Inventors: B. Kim Lee Sim, Minglin Li, Richard E. Stafford, Stephen L. Hoffman
-
Publication number: 20160175417Abstract: Disclosed are substantially purified Plasmodium sporozoites and preparations of Plasmodium sporozoites substantially separated from attendant non-sporozoite material, where the preparations of Plasmodium sporozoites have increasing levels of purity. Vaccines and pharmaceutical compositions comprising purified Plasmodium sporozoites are likewise provided. Methods of purifying preparations of Plasmodium sporozoites are also provided.Type: ApplicationFiled: January 21, 2016Publication date: June 23, 2016Applicant: Sanaria Inc.Inventors: B. Kim Lee SIM, Minglin LI, Richard E. STAFFORD, Stephen L. HOFFMAN
-
Patent number: 9241982Abstract: Disclosed are substantially purified Plasmodium sporozoites and preparations of Plasmodium sporozoites substantially separated from attendant non-sporozoite material, where the preparations of Plasmodium sporozoites have increasing levels of purity. Vaccines and pharmaceutical compositions comprising purified Plasmodium sporozoites are likewise provided. Methods of purifying preparations of Plasmodium sporozoites are also provided.Type: GrantFiled: March 27, 2015Date of Patent: January 26, 2016Assignee: SANARIA INC.Inventors: B. Kim Lee Sim, Minglin Li, Richard E. Stafford, Stephen L. Hoffman
-
Publication number: 20150313981Abstract: Disclosed are substantially purified Plasmodium sporozoites and preparations of Plasmodium sporozoites substantially separated from attendant non-sporozoite material, where the preparations of Plasmodium sporozoites have increasing levels of purity. Vaccines and pharmaceutical compositions comprising purified Plasmodium sporozoites are likewise provided. Methods of purifying preparations of Plasmodium sporozoites are also provided.Type: ApplicationFiled: March 27, 2015Publication date: November 5, 2015Applicant: Sanaria Inc.Inventors: B. Kim Lee SIM, Minglin LI, Richard E. STAFFORD, Stephen L. Hoffman
-
Patent number: 8992944Abstract: Disclosed are substantially purified Plasmodium sporozoites and preparations of Plasmodium sporozoites substantially separated from attendant non-sporozoite material, where the preparations of Plasmodium sporozoites have increasing levels of purity. Vaccines and pharmaceutical compositions comprising purified Plasmodium sporozoites are likewise provided. Methods of purifying preparations of Plasmodium sporozoites are also provided.Type: GrantFiled: December 28, 2012Date of Patent: March 31, 2015Assignee: Sanaria Inc.Inventors: B. Kim Lee Sim, Minglin Li, Richard E. Stafford, Stephen L. Hoffman
-
Patent number: 8821896Abstract: Disclosed are substantially purified Plasmodium sporozoites and preparations of Plasmodium sporozoites substantially separated from attendant non-sporozoite material, where the preparations of Plasmodium sporozoites have increasing levels of purity. Vaccines and pharmaceutical compositions comprising purified Plasmodium sporozoites are likewise provided. Methods of purifying preparations of Plasmodium sporozoites are also provided.Type: GrantFiled: December 28, 2012Date of Patent: September 2, 2014Assignee: Sanaria Inc.Inventors: B. Kim Lee Sim, Minglin Li, Richard E. Stafford, Stephen L. Hoffman
-
Publication number: 20130251750Abstract: Disclosed are substantially purified Plasmodium sporozoites and preparations of Plasmodium sporozoites substantially separated from attendant non-sporozoite material, where the preparations of Plasmodium sporozoites have increasing levels of purity. Vaccines and pharmaceutical compositions comprising purified Plasmodium sporozoites are likewise provided. Methods of purifying preparations of Plasmodium sporozoites are also provided.Type: ApplicationFiled: December 28, 2012Publication date: September 26, 2013Applicant: Sanaria Inc.Inventors: B. Kim Lee SIM, Minglin Li, Richard E. Stafford, Stephen L. Hoffman
-
Patent number: 8367810Abstract: Disclosed are substantially purified Plasmodium sporozoites and preparations of Plasmodium sporozoites substantially separated from attendant non-sporozoite material, where the preparations of Plasmodium sporozoites have increasing levels of purity. Vaccines and pharmaceutical compositions comprising purified Plasmodium sporozoites are likewise provided. Methods of purifying preparations of Plasmodium sporozoites are also provided.Type: GrantFiled: August 27, 2010Date of Patent: February 5, 2013Assignee: Sanaria Inc.Inventors: B. Kim Lee Sim, Minglin Li, Richard E. Stafford, Stephen L. Hoffman
-
Publication number: 20120058543Abstract: Disclosed are substantially purified Plasmodium sporozoites and preparations of Plasmodium sporozoites substantially separated from attendant non-sporozoite material, where the preparations of Plasmodium sporozoites have increasing levels of purity. Vaccines and pharmaceutical compositions comprising purified Plasmodium sporozoites are likewise provided. Methods of purifying preparations of Plasmodium sporozoites are also provided.Type: ApplicationFiled: August 27, 2010Publication date: March 8, 2012Applicant: Sanaria, Inc.Inventors: B. Kim Lee SIM, Minglin Li, Richard E. STAFFORD, Stephen L. HOFFMAN
-
Patent number: 8043625Abstract: Disclosed are substantially purified Plasmodium sporozoites and preparations of Plasmodium sporozoites substantially separated from attendant non-sporozoite material, where the preparations of Plasmodium sporozoites have increasing levels of purity. Vaccines and pharmaceutical compositions comprising purified Plasmodium sporozoites are likewise provided. Methods of purifying preparations of Plasmodium sporozoites are also provided.Type: GrantFiled: January 8, 2010Date of Patent: October 25, 2011Assignee: Sanaria Inc.Inventors: B. Kim Lee Sim, Minglin Li, Richard E. Stafford, Stephen L. Hoffman
-
Publication number: 20100183680Abstract: Disclosed are substantially purified Plasmodium sporozoites and preparations of Plasmodium sporozoites substantially separated from attendant non-sporozoite material, where the preparations of Plasmodium sporozoites have increasing levels of purity. Vaccines and pharmaceutical compositions comprising purified Plasmodium sporozoites are likewise provided. Methods of purifying preparations of Plasmodium sporozoites are also provided.Type: ApplicationFiled: January 8, 2010Publication date: July 22, 2010Inventors: B. Kim Lee Sim, Minglin Li, Richard E. Stafford, Stephen L. Hoffman
-
Patent number: 7749519Abstract: Malaria in humans is caused by infection with Plasmodium species parasites including P. vivax. The biology and immunobilogy of P. vivax is distinct from that of P. falciparum. Provided are unique synthetic polypeptides and DNA molecules which encode them. Each of these molecules correspond to regions of the circumsporozoite protein of P. vivax. Each molecule comprises sequences corresponding to several repeats of the central region of the Pv 210 variant fused to sequences corresponding to several repeats of the central region of the Pv 247 variant. Each molecule additionally comprises sequences corresponding to either the amino terminus, the carboxy terminus, or both the amino and carboxy termini of the PvCSP. Also provided are vaccines comprising these unique sequences and methods of using these vaccines and sequences to prevent and treat Pv malaria.Type: GrantFiled: December 11, 2006Date of Patent: July 6, 2010Inventors: Kim Lee Sim, Stephen Hoffman, Myriam Arevalo, Socrates Herrera